Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - CorneaResults: Of the 79 cytokines, chemokines and soluble receptors, wedetected 16 molecules that demonstrated a significant differences intears from Keratoconus patients. In cytokines, G-CSF (p
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - CorneaSupport: NIH, NEI, R44 EY017497, R43 EY021045, and RO1EY06819Program Number: 2061 Poster Board Number: D0200Presentation Time: 11:00 AM - 12:45 PMIn Vivo Administration of Interleukin-2 Increases CornealAllograft Survival through Expansion of CD4+CD25+ TRegulatory CellsMaryam Tahvildari, Parisa Emami-Naeini, Yihe Chen, MasahiroOmoto, Jing Hua, Sunil K. Chauhan, Reza Dana. Schepens EyeResearch Institute, Massachusetts Eye and Ear, Department ofOphthalmology, Harvard Medical School, Boston, MA.Purpose: T regulatory cells (Tregs) have a major role in inhibitinggrowth and differentiation of activated T cells following alloantigenstimulation, and it has been found that interleukin-2 (IL-2) is crucialin the generation and maintenance of these cells. In this study ofmurine corneal transplantation, we aimed to investigate the effect ofsystemic administration of IL-2 on corneal allograft survival.Methods: Corneal transplantation was performed on 8-10 week-oldmale BALB/c (H-2d) mice using C57BL/6 (H-2b) mice as donors.Prior to surgery, recipient mice received 3 intraperitoneal injections(once a day) of either IL-2 (1µg/20 g body weight, in 100µlphosphate buffer saline [PBS]) or PBS alone (as control). Injectionswere continued once daily for one week after surgery followed bytwice a week for another 4 weeks. Allografts were evaluated up to 5weeks post-transplantation and were scored using the standardopacity grading system (from 0 to +5). Frequencies ofCD4+CD25+Foxp3+ Tregs in the draining lymph nodes wereevaluated by flow cytometry on the day of transplantation (day 0),one week (day 7) and two weeks (day 14) afterwards. In addition, thesuppressive function of CD4+CD25+ Tregs derived from draininglymph nodes of recipient mice was evaluated one week aftertransplantation.Results: Of the six corneas transplanted in each group, 66.6% in theIL-2 treated group remained clear up to 5 weeks after surgerycompared to 33.3% in the control group; moreover, IL-2 treatmentdelayed the incidence of graft rejection with mean rejection time of32±1.4 days (mean±SD) for the IL-2 treated vs. 19.5±7.7 days for thecontrol group. Flow cytometric analysis showed significant increasesin the frequencies of CD4+CD25+Foxp3+ Tregs in the draininglymph nodes of recipient mice in the IL-2 treated group compared tothe control group at day 0 (14.54% vs. 10.25%, p=0.014), day 7(14.77% vs. 11.73%, p=0.009) and day 14 (16.15% vs. 12.41%,p=0.0007). Treg suppression assay revealed 16.05% increasedsuppression of effector T cells in the IL-2 treated group compared tothe control group one week after transplantation (p=0.01).Conclusions: According to our results, systemic administration ofIL-2 is capable of enhancing the frequencies and suppressive functionof CD4+CD25+Foxp3+ Tregs, and increases corneal allograftsurvival.Commercial Relationships: Maryam Tahvildari, None; ParisaEmami-Naeini, None; Yihe Chen, None; Masahiro Omoto, None;Jing Hua, None; Sunil K. Chauhan, None; Reza Dana, Allergan(C), Alcon (C), Bausch & Lomb (C), Eleven Bio (I), GSK (F),Novabay (C), Revision Optics (C), Novaliq (C), RIgel (F)Support: NIH Grant EY12963Program Number: 2062 Poster Board Number: D0201Presentation Time: 11:00 AM - 12:45 PMProteomic Analysis of Plasma and Mucosal Samples fromPatients with Stevens-Johnson Syndrome/Toxic EpidermalNecrolysisJulia Malalis 1 , Christine Mata 1 , Daniel Kahn 3 , Amy Lin 1 , Michael J.Mosier 2 , Charles S. Bouchard 1 , Josephine Cunanan 3 , Omer Iqbal 1, 3 ,Debra Hoppensteadt 3 , Jawed Fareed 3 . 1 Ophthalmology, LoyolaUniversity Chicago Stritch School of Medicine, Maywood, IL;2 Surgery, Loyola University Medical Center, Maywood, IL;3 Pathology, Loyola University Chicago Stritch School of Medicine,Maywood, IL.Purpose: Stevens-Johnson syndrome and toxic epidermal necrolysis(SJS/TEN) are life-threatening, immune-complex hypersensitivityreactions that affect the skin and mucous membranes, often resultingin significant ocular inflammation. The purpose of this study was todetermine and compare the proteomic and coagulation profile ofplasma and mucosal discharge samples in affected and unaffectedpatients.Methods: Following institutional review board approval, plasma andswabs from ocular, oral, and skin lesions were obtained from patientswith clinically suspected SJS/TEN (n=5). Two patients had biopsyprovenSJS/TEN. Three patients had alternative skin diagnoses notconsistent with SJS/TEN and were considered abnormal controls.Samples from normal healthy controls were also obtained. Followingcentrifugation, the plasma was frozen at -70°C and later thawed andanalyzed to determine thrombin-antithrombin complex (TAT,Dade®, Marburg, Germany), fibrinopeptide (F1.2, Dade®),plasminogen activator inhibitor-1 (PAI-1, Diagnostica Stago®,Asnieres Sur Seine, France), ZYMUPHEN platelet microparticleactivity (Hyphen® BioMed, Neuville-Sur Oise, France),HEMOCLOT protein C (Stago®), and STACHROME antithrombin(Stago®), using ELISA kits as per manufacturer’s instructions. Theswabs were immediately frozen at -70°C and later thawed. Thedischarges were isolated following addition of 0.25 ml of saline toeach swab and double centrifugation. The discharges and plasmasamples were analyzed using SELDI-TOF technique.Results: Analyses of the SJS/TEN plasma samples revealed amarked increase in the TAT complexes (6.3±5.9µg/ml), F1.2(430.4±202.4 pmol/L), platelet microparticles (13.1±9.3nM) andprotein C levels (90.5±63.4%), with a corresponding decrease in PAI-1 (53.3±18.8ng/ml) and antithrombin levels (80.7±42.4%) comparedto normal control human plasma, suggesting a procoagulant state.Protein chip array of the SJS/TEN skin and oral mucosal samplesexhibited two major peaks at 14.2 kDa and 15.6 kDa, in the samemolecular weight range as recombinant human granulysin, amolecule implicated in the pathophysiology of SJS/TEN. Thesepeaks were not present in the control group.Conclusions: Procoagulant factors and unique peaks suggestive ofgranulysin may lead to the development of targeted therapy aimed toattenuate local and systemic inflammatory processes in patients withSJS/TEN.Commercial Relationships: Julia Malalis, None; Christine Mata,None; Daniel Kahn, None; Amy Lin, None; Michael J. Mosier,None; Charles S. Bouchard, None; Josephine Cunanan, None;Omer Iqbal, None; Debra Hoppensteadt, None; Jawed Fareed,NoneSupport: Illinois Society for the Prevention of Blindness (ISPB)GrantProgram Number: 2063 Poster Board Number: D0202Presentation Time: 11:00 AM - 12:45 PMMorphologic Dendritic Immune Cells Parameters RevealDifferential Characteristics between the Central and PeripheralCornea: an In Vivo Confocal Microscopy Normative DataClara M. Colon 1 , Bernardo M. Cavalcanti 1, 2 , Shruti Aggarwal 1 ,Andrea Cruzat 1, 2 , Candice Williams 1 , Douglas Critser 4 , Amy Watts 3 ,Christine W. Sindt 4 , Pedram Hamrah 1, 2 . 1 Department of©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.
Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10:
Page 13 and 14:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81: ARVO 2013 Annual Meeting Abstracts
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?